| Title | Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Sierra-Madero, Juan G., Susan S. Ellenberg, Mohammed S. Rassool, Ann Tierney, Pablo F. Belaunzarán-Zamudio, Alondra López-Martínez, Alicia Piñeirúa-Menéndez, Luis J. Montaner, Livio Azzoni, César Rivera Benítez, Irini Sereti, Jaime Andrade-Villanueva, Juan L. Mosqueda-Gómez, Benigno Rodriguez, Ian Sanne, and Michael M. Lederman |
| Corporate Authors | CADIRIS study team |
| Journal | The lancet. HIV |
| Volume | 1 |
| Issue | 2 |
| Pagination | e60-7 |
| Date Published | 2014 Nov |
| ISSN | 2352-3018 |
| Abstract | Immune reconstitution inflammatory syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in patients with HIV. IRIS is associated with an increased risk of admission to hospital and death. We assessed whether CCR5 blockade with maraviroc reduces the risk of IRIS. |
| DOI | 10.1016/S2352-3018(14)70027-X |
| Alternate Journal | Lancet HIV |
